» Articles » PMID: 10439047

The Transcription Coactivator HTIF1 and a Related Protein Are Fused to the RET Receptor Tyrosine Kinase in Childhood Papillary Thyroid Carcinomas

Overview
Journal Oncogene
Date 1999 Aug 10
PMID 10439047
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Children exposed to radioactive iodine as a consequence of the Chernobyl reactor accident have an increased risk of papillary thyroid carcinomas (PTC). The predominant molecular lesions in these tumors are rearrangements of the RET receptor tyrosine kinase (tk). Here we report on two novel types of RET rearrangement, PTC6 and 7, and describe the fusion products and the ret fused gene (rfg) proteins. Like the other rfg proteins identified so far they are ubiquitously expressed, not membrane-bound and contain coiled coil domains required for constitutive activation of the ret tk domain. In the PTC6 rearrangement the ret tk domain is fused to the aminoterminal part of the human transcription intermediary factor htif 1. In the PTC7 rearrangement the ret tk domain is fused to a novel protein that is strongly related to htif1. Like htif1 it contains a RBCC motif (ring finger, B boxes, coiled coil domain) located in the aminoterminal part and a phd finger and a bromodomain in the carboxyterminal part. Htif1 and related proteins are transcription coactivators for nuclear receptors, thus participating in controlling cellular development, differentiation and homeostasis. This is the first report on their involvement in human thyroid carcinogenesis.

Citing Articles

The Role and Mechanism of TRIM Proteins in Gastric Cancer.

Wu W, Yang J, Yu T, Zou Z, Huang X Cells. 2025; 13(24.

PMID: 39768197 PMC: 11674240. DOI: 10.3390/cells13242107.


Genetic alterations landscape in paediatric thyroid tumours and/or differentiated thyroid cancer: Systematic review.

de Sousa M, Nunes I, Christiano Y, Sisdelli L, Cerutti J Rev Endocr Metab Disord. 2023; 25(1):35-51.

PMID: 37874477 DOI: 10.1007/s11154-023-09840-2.


RET kinase inhibitors for -altered thyroid cancers.

Vodopivec D, Hu M Ther Adv Med Oncol. 2022; 14:17588359221101691.

PMID: 35756966 PMC: 9218446. DOI: 10.1177/17588359221101691.


Development of an RNA sequencing panel to detect gene fusions in thyroid cancer.

Kim D, Jung S, Chung Y Genomics Inform. 2022; 19(4):e41.

PMID: 35172474 PMC: 8752984. DOI: 10.5808/gi.21061.


Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.

Liu M, Chen P, Hu H, Ou-Yang D, Khushbu R, Tan H J Cancer Res Clin Oncol. 2021; 147(2):323-337.

PMID: 33387037 DOI: 10.1007/s00432-020-03491-5.